December 3, 2022Liver InternationalOpen Access

Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

AEAkiko EguchiMie University MIMotoh IwasaMie University HNHayato NakagawaMie University

Discussion

Member takes

Implication

May guide noninvasive monitoring and therapy development in MAFLD; leaves open clinical adoption pending prospective validation.

Structured PICO

Population

Individuals with fatty liver disease, including non-alcoholic fatty liver disease (NAFLD), alcohol-associated liver disease (ALD), and metabolic associated fatty liver disease (MAFLD)

Intervention

Extracellular vesicles (EVs) as biomarkers and therapeutic targets (e.g., mesenchymal stem cell-derived EVs)

Extracellular vesicles hold promise as both diagnostic biomarkers and novel therapeutic agents for metabolic associated fatty liver disease.

Cite This Study

Eguchi et al. (2022) studied this question.

synapsesocial.com/papers/6a7e13a28019269472df3b2f https://doi.org/10.1111/liv.15490

View Full Paper

Ask AI

Bookmark

Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider